Kura Oncology, Inc. (KURA) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Kura Oncology, Inc. (NASDAQ:KURA) is held by 199 institutional firms.

• The collective stake of institutional investors in Kura Oncology moved to 96.3% in September 2025, a shift up from the 92.8% reported for June 2025.
• The company experienced a 6.26% quarterly change in institutional shares held, alongside an increase of 11.17% in total owners annually.
• During the quarter, 119 institutions bought more Kura Oncology shares, 51 sold shares, and 29 of the 199 total investors held their position steady.
• The aggregate institutional position in Kura Oncology now stands at 83.94Mn shares as of September 2025, after investors increased their holdings (up by 4.95Mn shares quarter on quarter which is up 1.76Mn shares year over year).
• As of September 30, 2025, BlackRock, Inc. held Kura Oncology's largest shareholding position with over 9.52Mn shares, representing 10.91% of total outstanding shares.
• Among the most significant buyers of Kura Oncology during September 2025 were GOLDMAN SACHS GROUP INC (1.68Mn), AQR CAPITAL MANAGEMENT LLC (1.30Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (1.12Mn), BVF INC/IL (863.03K), CITADEL ADVISORS LLC (808.82K).
• Leading sellers of Kura Oncology stock in September 2025 included EcoR1 Capital, LLC (3.33Mn), ARMISTICE CAPITAL, LLC (1.53Mn), JANUS HENDERSON GROUP PLC (561.91K), MILLENNIUM MANAGEMENT LLC (527.82K), Prosight Management, LP (422.67K).
• The top 10 institutional holders of Kura Oncology for the quarter ending September 2025 included BlackRock, Inc. (9.52Mn), BVF INC/IL (8.62Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (8.12Mn), VANGUARD GROUP INC (5.47Mn), ARMISTICE CAPITAL, LLC (4.67Mn), STATE STREET CORP (3.34Mn), Prosight Management, LP (2.76Mn), GOLDMAN SACHS GROUP INC (2.61Mn), AQR CAPITAL MANAGEMENT LLC (2.24Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (2.22Mn).